Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of SCTB35 plus SCTB41 with or without chemotherapy in non-Hodgkin lymphoma
CTR20263618Phase 2Active
- Sponsor
- Sinocelltech Group Limited
- Start
- Sep 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SCTB35, SCTB41 in non-Hodgkin lymphoma (NHL), sponsored by Sinocelltech Group Limited. Started Sep 2026; status: active.
02
Drugs
SCTB35SCTB41
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on CTR20263618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263618.